- Home
- INSM
INSM
Insmed Incorporated
as 05-08-2025 4:00pm EST
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
| Founded: | 1988 | Country: | United States |
| Employees: | N/A | City: | BRIDGEWATER |
| Market Cap: | 12.6B | IPO Year: | 2000 |
| Target Price: | $95.36 | AVG Volume (30 days): | 2.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.89 | EPS Growth: | N/A |
| 52 Week Low/High: | $21.92 - $84.91 | Next Earning Date: | 05-08-2025 |
| Revenue: | $381,030,000 | Revenue Growth: | 20.77% |
| Revenue Growth (this year): | 30.36% | Revenue Growth (next year): | 115.55% |
Stock Insider Trading Activity of Insmed Incorporated (INSM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Lewis William | INSM | Chair and CEO | May 1 '25 | Sell | $72.51 | 6,830 | $495,667.74 | 233,924 | |
| Lewis William | INSM | Chair and CEO | Apr 15 '25 | Sell | $70.49 | 6,830 | $479,176.92 | 233,924 | |
| Lewis William | INSM | Chair and CEO | Apr 1 '25 | Sell | $73.94 | 6,830 | $502,577.03 | 233,924 | |
| Lewis William | INSM | Chair and CEO | Mar 17 '25 | Sell | $76.90 | 25,580 | $1,970,420.71 | 233,924 | |
| Lewis William | INSM | Chair and CEO | Mar 3 '25 | Sell | $78.70 | 25,580 | $1,989,796.50 | 233,924 | |
| Lewis William | INSM | Chair and CEO | Feb 18 '25 | Sell | $80.93 | 25,580 | $2,072,721.15 | 233,924 | |
| Bonstein Sara | INSM | Chief Financial Officer | Feb 18 '25 | Sell | $80.64 | 18,322 | $1,471,394.16 | 119,563 | |
| Bonstein Sara | INSM | Chief Financial Officer | Feb 11 '25 | Sell | $80.00 | 18,321 | $1,465,680.00 | 119,563 | |
| Flammer Martina M.D. | INSM | Chief Medical Officer | Feb 10 '25 | Sell | $78.24 | 37,828 | $2,973,484.92 | 123,175 | |
| Adsett Roger | INSM | Chief Operating Officer | Feb 10 '25 | Sell | $78.24 | 42,975 | $3,378,066.75 | 172,223 |
Latest Insmed Incorporated News
INSM Breaking Stock News: Dive into INSM Ticker-Specific Updates for Smart Investing
MT Newswires
a day ago
Insmed Q1 Net Loss Widens, Revenue Increases; 2025 Revenue Guidance Maintained
Associated Press Finance
a day ago
Insmed: Q1 Earnings Snapshot
PR Newswire
a day ago
Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update
Insider Monkey
5 days ago
Insmed Incorporated (INSM): Among the Large-Cap Stocks Insiders and Short Sellers Are Dumping Like Crazy
MT Newswires
7 days ago
Insmed Insider Sold Shares Worth $495,668, According to a Recent SEC Filing
Zacks
8 days ago
Earnings Preview: Insmed (INSM) Q1 Earnings Expected to Decline
Insider Monkey
9 days ago
Insmed Incorporated (INSM): Among Billionaire George Soros’ Mid-Cap Stocks With Huge Upside Potential
PR Newswire
10 days ago
Insmed To Present at the BofA Securities 2025 Health Care Conference
Compare INSM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INSM Insmed Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.